Evidence map›Paper›PMID 40432814›Full record

ArticleERJ open research2025

The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.

David J F Smith, Nancy M Y Teng, Emma K Denneny, Puja Mehta, Stefan C Stanel, John F Blaikley, Rachel C Chambers, Nazia Chaudhuri, Ben Garfield, Justin L Garner and 16 more

Abstract read
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Sympathetic denervation alters pulmonary microbiota diversity and composition in mice.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

David J F SmithNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-9055-7977
Nancy M Y TengNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-0008-8404
Emma K DennenyUniversity College London, London, UK.
Puja MehtaUniversity College London, London, UK.ORCID https://orcid.org/0000-0001-9459-9306
Stefan C StanelUniversity of Manchester, Manchester, UK.
John F BlaikleyUniversity of Manchester, Manchester, UK.
Rachel C ChambersUniversity College London, London, UK.ORCID https://orcid.org/0000-0003-1370-9417
Nazia ChaudhuriUlster University, Belfast, UK.
Ben GarfieldRoyal Brompton & Harefield Hospitals, London, UK.
Justin L GarnerNational Heart and Lung Institute, Imperial College London, London, UK.
Peter M GeorgeNational Heart and Lung Institute, Imperial College London, London, UK.
Poonam GhaiNational Heart and Lung Institute, Imperial College London, London, UK.
Onn Min KonNational Heart and Lung Institute, Imperial College London, London, UK.
Yonghua LiDivision of Pulmonary and Critical Care Medicine, New York University, New York, NY, USA.
William D-C ManNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-3782-659X
Joanna C PorterUniversity College London, London, UK.ORCID https://orcid.org/0000-0002-7307-169X
Valerie QuinnNational Heart and Lung Institute, Imperial College London, London, UK.
Pilar Rivera-OrtegaManchester University NHS Foundation Trust, Manchester, UK.
Clare RossImperial College Healthcare NHS Trust, London, UK.
Leopoldo N SegalDivision of Pulmonary and Critical Care Medicine, New York University, New York, NY, USA.ORCID https://orcid.org/0000-0003-3559-9431
Simone A WalkerNational Heart and Lung Institute, Imperial College London, London, UK.
Benjamin G WuDivision of Pulmonary and Critical Care Medicine, New York University, New York, NY, USA.
Clare M LloydNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-8977-6726
Iain StewartNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-1340-2688
R Gisli JenkinsNational Heart and Lung Institute, Imperial College London, London, UK.
Philip L MolyneauxNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-1301-8800

Funding

Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancerU2CCA271890 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Leopoldo Nicolas Segal · 2023 to 2026
$4.7M
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancerR37CA244775 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Leopoldo Nicolas Segal · 2020 to 2026
$4.7M
Age related loss of immune resilience during response to severe respiratory viral infectionsU01AG088351 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHRISTIAN FORST, Leopoldo Nicolas Segal · 2024 to 2026
$1.5M
BIOREPOSITORY OPTIMIZATION AND USE FOR ENDOTYPING CRITICALLY ILL SARS-COV-2 INFECTED PATIENTSR33GM147800 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGAL, LEOPOLDO NICOLAS · 2024 to 2025
$1.5M
BLRD VA IK2 BX005309NCI NIH HHS R37 CA244775NCI NIH HHS U2C CA271890NIA NIH HHS U01 AG088351NIGMS NIH HHS R33 GM147800Wellcome Trust
6 · The paper itself

Abstract

Introduction: Up to 11% of patients are left with residual lung abnormalities following COVID-19 infection. It is unclear whether these changes resolve over time or progress to fibrosis. The airway microbiome is altered in interstitial lung disease, potentially contributing to pathogenesis and disease progression. We hypothesised that the airway microbiome in patients with post-COVID-19 residual lung abnormalities may be altered. Methods: The POST COVID-19 interstitial lung DiseasE (POSTCODE) study recruited subjects with post-COVID-19 residual lung abnormalities for bronchoscopy. 16S ribosomal RNA gene amplicon sequencing was performed on DNA extracted from bronchoalveolar lavage fluid and compared with that from patients with idiopathic pulmonary fibrosis, fibrotic hypersensitivity pneumonitis and control subjects. Results: 28 subjects with post-COVID-19 residual lung abnormalities were recruited an average of 11 months after infection. No significant associations were found between the lower airway microbiome or bacterial burden and disease severity or trajectory. There was no difference in bacterial burden between post-COVID-19 patients and interstitial lung disease or control subjects. Furthermore, no differences in microbial composition were observed between these patients and those with fibrotic hypersensitivity pneumonitis or controls. However, compared with idiopathic pulmonary fibrosis, there was an increased abundance of Conclusions: The microbiome and bacterial burden in the lower airways of subjects with post-COVID-19 residual lung abnormalities do not differ from those of controls. The microbiome differs from idiopathic pulmonary fibrosis. This, and the absence of associations between microbial features and disease severity or clinical outcomes, suggests that the microbiome is unlikely to contribute to residual lung abnormalities in patients recovering from COVID-19 infection.

Identifiers

PMID40432814
PMCPMC12107383

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.